GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » US Stem Cell Inc (OTCPK:USRM) » Definitions » Cyclically Adjusted PB Ratio

US Stem Cell (US Stem Cell) Cyclically Adjusted PB Ratio : (As of Jun. 06, 2024)


View and export this data going back to 2008. Start your Free Trial

What is US Stem Cell Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


US Stem Cell Cyclically Adjusted PB Ratio Historical Data

The historical data trend for US Stem Cell's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Stem Cell Cyclically Adjusted PB Ratio Chart

US Stem Cell Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

US Stem Cell Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of US Stem Cell's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, US Stem Cell's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


US Stem Cell's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, US Stem Cell's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where US Stem Cell's Cyclically Adjusted PB Ratio falls into.



US Stem Cell Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

US Stem Cell's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2022 is calculated as:

For example, US Stem Cell's adjusted Book Value per Share data for the three months ended in Dec. 2022 was:

Adj_Book=Book Value per Share/CPI of Dec. 2022 (Change)*Current CPI (Dec. 2022)
=-0.023/125.2218*125.2218
=-0.023

Current CPI (Dec. 2022) = 125.2218.

US Stem Cell Quarterly Data

Book Value per Share CPI Adj_Book
201303 -73.580 98.209 -93.818
201306 -60.789 98.518 -77.266
201309 -42.813 98.790 -54.268
201312 -36.249 98.326 -46.164
201403 -28.970 99.695 -36.388
201406 -20.585 100.560 -25.633
201409 -20.298 100.428 -25.309
201412 -18.771 99.070 -23.726
201503 -16.260 99.621 -20.439
201506 -11.542 100.684 -14.355
201509 -9.297 100.392 -11.596
201512 -4.479 99.792 -5.620
201603 -2.807 100.470 -3.499
201606 -0.863 101.688 -1.063
201609 -0.300 101.861 -0.369
201612 -0.063 101.863 -0.077
201703 -0.023 102.862 -0.028
201706 -0.021 103.349 -0.025
201709 -0.022 104.136 -0.026
201712 -0.021 104.011 -0.025
201803 -0.018 105.290 -0.021
201806 -0.019 106.317 -0.022
201809 -0.019 106.507 -0.022
201812 -0.018 105.998 -0.021
201903 -0.018 107.251 -0.021
201906 -0.019 108.070 -0.022
201909 -0.023 108.329 -0.027
201912 -0.023 108.420 -0.027
202003 -0.023 108.902 -0.026
202006 -0.024 108.767 -0.028
202009 -0.026 109.815 -0.030
202012 -0.027 109.897 -0.031
202103 -0.025 111.754 -0.028
202106 -0.026 114.631 -0.028
202109 -0.027 115.734 -0.029
202112 -0.025 117.630 -0.027
202203 -0.023 121.301 -0.024
202206 -0.023 125.017 -0.023
202209 -0.022 125.227 -0.022
202212 -0.023 125.222 -0.023

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


US Stem Cell  (OTCPK:USRM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


US Stem Cell Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of US Stem Cell's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


US Stem Cell (US Stem Cell) Business Description

Traded in Other Exchanges
N/A
Address
1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
Executives
Murphy William P Jr director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Gregory Knutson director 14855 ABERDEN STREET NE, HAM LAKE MN 55304
Mark P Borman director 5240 WASHBURN AVENUE SOUTH, MINNEAPOLIS MN 55410
Charles A Hart director 19345 RHINESTONE STREET NW, ANOKA MN 55303
Sheldon T. Anderson director 1121 CRANDON BLVD., APT. D-103, KEY BISCAYNE FL 33149
Kristin C Comella officer: Chief Science Officer 1310 LEEWARD WAY, WESTON FL 33327
A Jones Lee director 54 LOCKE LAKE RD, FRIDLEY MN 55432
Karl Groth director 1160 FIFTH AVENUE, SUITE 207, NEW YORK NY 10029
Matthew J Fendrich officer: Vice President,Sales&Marketing 482 PEACOCK LANE SOUTH, JUPITER FL 33458
Alan P Timmins director 1111 MAIN STREET, SUITE 600, VANCOUVER WA 98660
Bruce C Carson director 11850 COTTONWOOD STREET NW, COON RAPIDS MN 55448
Howard J Leonhardt director, 10 percent owner, officer: Executive Chairman & CTO 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Bromley R Scott officer: VP of Public Relations 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Richard Iii Spencer director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325
Mike Tomas director 13794 NW 4TH STREET, SUITE 212, SUNRISE FL 33325

US Stem Cell (US Stem Cell) Headlines